Myriad Genetics, a Salt Lake City-based provider of genetic testing and precision medicine, has agreed to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise Tumor Test, the Precise Liquid Test and IPG’s CLIA-certified laboratory in St. George where the Precise Tumor Test is currently performed.
The acquisition is expected to close on Feb. 1, subject to customary closing conditions. Financial details were not disclosed.
By bringing the Precise Tumor and Precise Liquid tests in-house, Myriad will open up new opportunities for Please log in to see the rest of this story.
